Long-Term Cardiac Follow-up 4–13 Years after Anthracycline Therapy

  • L. Steinherz
  • M. L. Murphy
  • P. Steinherz
  • J. Robins
  • C. Tan

Abstract

Myocardial damage is the major limiting toxicity of anthracycline chemotherapy. Cardiac decompensation can occur during therapy or months after the last dose, and it entails a high morbidity [1–3]. The immediate clinical course and short-term prognosis has been well documented, and the incidence has been definitely correlated with the cumulative dose of anthracycline received [1–3]. Although dose limitation, noninvasive monitoring, and cardiac biopsy have reduced the incidence of cardiac failure [4], clinical toxicity still occurs [5]. Moreover, it is clear that even at low doses, subclinical myocardial damage is seen pathologically on biopsy specimens [3, 5]. Improvement of myocardial function has been reported in surviving patients during the first 4 years after treatment [4, 5]. However, there have been no greater range studies of either the outcome of patients with clinical anthracycline cardiomyopathy or the cardiac status of asymptomatic patients who received anthracyclines in the range reported to be associated with pathologic changes. The long-term cardiac status is particularly important in children who look forward to decades of active life once their cancer is eradicated. We reviewed the history and echocardiograms of 100 patients who both received daunorubicin and/or doxorubicin in multiagent chemotherapy and survived from 4–13 years after this therapy was discontinued.

Keywords

Toxicity Lymphoma Leukemia Sarcoma Doxorubicin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Lefrak EA, Pitha J, Rosenheim S, Gottlieb J: A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 32: 302, 1973.PubMedCrossRefGoogle Scholar
  2. 2.
    Gilladoga AC, Manuel C, Tan CTC, Wollner N, Sternberg S, Murphy L: The cardiotoxicity of adriamycin and daunomycin in children. Cancer 37: 1070, 1976.PubMedCrossRefGoogle Scholar
  3. 3.
    Bristow MR, Billinghem ME, Mason JW, Daniels JR: Clinical spectrum of anthracycline cardiotoxicity. Cancer Treat Rep 62: 873, 1978.PubMedGoogle Scholar
  4. 4.
    Bloom K, Bini R, Williams C, Sonley M, Gribbin M: Echocardiography in adriamycin cardiotoxicity. Cancer 41: 1265, 1978.PubMedCrossRefGoogle Scholar
  5. 5.
    Dresdale A, Bonow R, Wesley R, Palmeri S, Barr L, Mathison D, Dan-Gelo T, Rosenberg S: Prospective evaluation of doxorubicin induced cardiomyo pathy resulting from post surgical adjuvant treatment of patients with soft tissuf sarcomas. Cancer 52: 51, 1983.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1986

Authors and Affiliations

  • L. Steinherz
  • M. L. Murphy
  • P. Steinherz
  • J. Robins
  • C. Tan

There are no affiliations available

Personalised recommendations